Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma
Top Cited Papers
- 15 January 2010
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 181 (2) , 116-124
- https://doi.org/10.1164/rccm.200903-0354oc
Abstract
Rationale: Bronchial thermoplasty (BT) is a bronchoscopic procedure in which controlled thermal energy is applied to the airway wall to decrease smooth muscle. Objectives: To evaluate the effectiveness and safety of BT versus a sham procedure in subjects with severe asthma who remain symptomatic despite treatment with high-dose inhaled corticosteroids and long-acting β2-agonists. Methods: A total of 288 adult subjects (Intent-to-Treat [ITT]) randomized to BT or sham control underwent three bronchoscopy procedures. Primary outcome was the difference in Asthma Quality of Life Questionnaire (AQLQ) scores from baseline to average of 6, 9, and 12 months (integrated AQLQ). Adverse events and health care use were collected to assess safety. Statistical design and analysis of the primary endpoint was Bayesian. Target posterior probability of superiority (PPS) of BT over sham was 95%, except for the primary endpoint (96.4%). Measurements and Main Results: The improvement from baseline in the integrated AQLQ score was superior in the BT group compared with sham (BT, 1.35 ± 1.10; sham, 1.16 ± 1.23 [PPS, 96.0% ITT and 97.9% per protocol]). Seventy-nine percent of BT and 64% of sham subjects achieved changes in AQLQ of 0.5 or greater (PPS, 99.6%). Six percent more BT subjects were hospitalized in the treatment period (up to 6 wk after BT). In the posttreatment period (6–52 wk after BT), the BT group experienced fewer severe exacerbations, emergency department (ED) visits, and days missed from work/school compared with the sham group (PPS, 95.5, 99.9, and 99.3%, respectively). Conclusions: BT in subjects with severe asthma improves asthma-specific quality of life with a reduction in severe exacerbations and healthcare use in the posttreatment period. Clinical trial registered with www.clinialtrials.gov (NCT00231114).Keywords
This publication has 34 references indexed in Scilit:
- Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research CentersJournal of Allergy and Clinical Immunology, 2009
- Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trialThe Lancet, 2008
- The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA2LEN reviewAllergy, 2008
- Quality‐of‐life and asthma‐severity in general population asthmatics: results of the ECRHS II studyAllergy, 2008
- Clinical Pearls for Bronchial ThermoplastyJournal of Bronchology, 2007
- Asthma in older adults: observations from the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) studyAnnals of Allergy, Asthma & Immunology, 2006
- Health-related quality of life predicts emergency department utilization for patients with asthmaAnnals of Emergency Medicine, 2004
- The Pursuit of Balance Using Stratified and Dynamic Randomization Techniques: An OverviewDrug Information Journal, 2003
- Health-related quality of life and future health care utilization for asthmaAnnals of Allergy, Asthma & Immunology, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001